| 11.09.21 | Mirati shares jump on Keytruda-KRAS combo peak; Novartis hammers another nail in its ill-fated $2.6B Xencor coffin

Klicken Sie hier, um Fiercebiotech.com zu abonnieren

Laden...

3 jahre vor

Html
Text

Join an Innovative Study Start-Up Team Transforming the Start-Up Process

Do you have a passion for disrupting and improving process? Premier Research’s Study Start-Up Team is looking for people to help improve the way the biotech industry achieves their clinical research objectives and helps patients. Learn more About our Study Start-Up Roles & Apply Today.

Today's Rundown

Seeking an edge over Amgen, Mirati advances lower KRAS dose in Keytruda combo to improve tolerability Novartis dumps 2nd bispecific from $2.6B Xencor pact, dealing further blow to hopes for blood cancer target Arbor's autumn: A $1.2B Vertex pact, now a $215M series B for liver, CNS diseases Sponsored: A New Reference Model for Clinical Trial Recruitment, Enrollment and Retention Success He got the first postpartum depression drug to market. Now, ex-Sage CMO takes helm at Ancora to revive a Taisho drug OcuTerra snags $35M for phase 2 trial of eye drop with former Allergan CEO as chair Flagship unveils its next RNA bet with $50M for Alltrna to explore thousands of genetic diseases using transfer RNA Alcon scopes out $475M acquisition of glaucoma stent maker Ivantis Drugmakers get mixed bag in lawsuit rulings over 340B contract pharmacy moves Bristol Myers Squibb's Opdivo posts another win in early lung cancer, but debate over treatment approach likely remains

Featured Story

Seeking an edge over Amgen, Mirati advances lower KRAS dose in Keytruda combo to improve tolerability

By Nick Paul Taylor

Mirati Therapeutics is looking to a KRAS-Keytruda combination to give it an edge over Amgen in lung cancer. After lowering the dose of its KRAS drug, Mirati saw around 60% of first-line patients respond to the combination—and lessened the tolerability concerns that initially held back the cocktail.

This week's sponsor is New Product Planning.

Novartis dumps 2nd bispecific from $2.6B Xencor pact, dealing further blow to hopes for blood cancer target

By Nick Paul Taylor

Novartis has hacked off another piece of its $2.6 billion deal with Xencor, terminating its rights to a CD123xCD3 blood cancer bispecific that had a troubled time in early clinical development.

Arbor's autumn: A $1.2B Vertex pact, now a $215M series B for liver, CNS diseases

By Kyle LaHucik

Just three months after a $1.2 billion pact with Vertex, Arbor Biotechnologies has hauled in $215 million in a series B to bankroll its work in gene editing tech. The round includes financing from Vertex, Temasek, Ally Bridge Group and TCG Crossover.

In its quest to revive a failed Taisho depression drug, Ancora Bio needed a leader with experience getting a therapy to market for the depression field. So, the Joe Jimenez-founded biotech has snagged Sage CMO Stephen Kanes, who secured the first FDA approval for a postpartum depression drug.

OcuTerra snags $35M for phase 2 trial of eye drop with former Allergan CEO as chair

By Kyle LaHucik

After rebranding from SciFluor Life Sciences and adding Centrexion co-founder Kerrie Brady as CEO last year, OcuTerra Therapeutics is ready for its next phase. The biotech secured $35 million to bankroll a phase 2 trial of its single asset.

Flagship unveils its next RNA bet with $50M for Alltrna to explore thousands of genetic diseases using transfer RNA

By Kyle LaHucik

Flagship helped lead the way in messenger RNA by incubating Moderna. Now, the biotech founder wants to revolutionize transfer RNAs with $50 million dedicated to Flagship's newest venture, Alltrna.

Alcon scopes out $475M acquisition of glaucoma stent maker Ivantis

By Andrea Park

Three years after Alcon pulled its CyPass Micro-Stent from the market due to safety concerns, the Novartis spinoff has found another glaucoma treatment device to take its place.

Drugmakers get mixed bag in lawsuit rulings over 340B contract pharmacy moves

By Robert King

Drugmakers got mixed results in two legal rulings on their ability to restrict sales of drugs discounted under the 340B program to contract pharmacies.

Bristol Myers Squibb's Opdivo posts another win in early lung cancer, but debate over treatment approach likely remains

By Angus Liu

Bristol Myers Squibb has expanded Opdivo’s first-in-class win in pre-surgery non-small cell lung cancer, teeing up a potential FDA filing. Opdivo added to neoadjuvant chemotherapy before surgery improved event-free survival in early lung cancer, the company said.

Maintain consistency with reliable media manufacturing solutions

Achieving consistency when scaling up your proprietary media formulation is essential. Join forces with the trusted pioneer of scalable bioprocessing solutions for reliable cGMP media manufacturing. Find out more.